Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Leyyur is a preclinical-stage non-hormonal contraceptive nanogel developed by Biom Pharmaceuticals. It is designed for topical vaginal administration to provide a contraceptive effect without the systemic side effects or hormonal disruptions associated with traditional birth control methods. The product is being advanced through the FDA 510(k) medical device pathway, which suggests its primary mechanism of action is physical or mechanical rather than pharmacological. This likely involves the maintenance of an acidic vaginal environment inhospitable to sperm or the creation of a physical barrier that inhibits sperm motility and penetration. Leyyur utilizes Biom Pharmaceuticals' proprietary nanogel technology to ensure effective delivery and localized action within the vaginal tract.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Leyyur.